Andrea Loewen - Mar 7, 2023 Form 4 Insider Report for REATA PHARMACEUTICALS INC (RETA)

Role
SVP, Global Regulatory Affairs
Signature
/s/ Tracy Herson, attorney-in-fact
Stock symbol
RETA
Transactions as of
Mar 7, 2023
Transactions value $
-$1,178,337
Form type
4
Date filed
3/9/2023, 03:47 PM
Previous filing
Mar 6, 2023
Next filing
May 16, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RETA Class A common stock Options Exercise $410K +15K +35.05% $27.32 57.8K Mar 7, 2023 Direct
transaction RETA Class A common stock Sale -$1.49M -17.8K -30.86% $83.36 40K Mar 7, 2023 Direct F1
transaction RETA Class A common stock Sale -$101K -1.2K -3% $84.44 38.8K Mar 7, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RETA Employee Stock Option (right to buy) Options Exercise $0 -15K -30% $0.00 35K Mar 7, 2023 Class A common stock 15K $27.32 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $83.00 to $83.90. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $84.00 to $84.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3 The options began vesting in sixteen equal installments beginning on April 3, 2022. On February 28, 2023, based on the satisfaction of certain performance criteria, the options scheduled to vest on April 3, 2025, July 3, 2025, October 3, 2025, and January 3, 2026 vested immediately. The remainder of the vesting schedule will continue as originally stated, subject to continued service through each vesting date.